文献速递神经肌肉病认知障碍与痴呆

C9orf72重复扩增携带者的生存与预后因素:系统综述与Meta分析

Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Neurol · 2020-01-01

该系统综述与Meta分析纳入206项研究共1060例C9orf72重复扩增携带者,比较不同表型的生存期并分析预后因素。结果显示c9ALS中位生存2.8年、c9FTD 9.0年、c9ALS-FTD 3.0年;发病年龄较大与生存期缩短相关,球部起病与c9ALS生存期缩短相关,而家族史、性别等与生存期无显著关联。

要点

  • C9orf72重复扩增携带者中,c9ALS中位生存2.8年,c9FTD 9.0年,c9ALS-FTD 3.0年。
  • 发病年龄较大与c9ALS、c9FTD和c9ALS-FTD生存期缩短独立相关。
  • 球部起病与c9ALS生存期缩短相关,家族史、性别等与生存期无显著关联。

核心结论

  • 研究识别了C9orf72重复扩增相关疾病中与生存相关的若干因素,包括发病年龄和球部起病。
  • 尽管方法学存在固有局限,但所报告的预后因素与所考察的偏倚指标无显著关联。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase等数据库2011年1月至2019年1月文献。
  • 最终纳入206项研究,共1060例经确认的C9orf72重复扩增携带者,排除197例重复病例。
  • 采用单变量和多变量Cox回归合成数据,以风险比(HR)和95%置信区间(95%CI)表示。

主要发现

  • c9ALS中位生存期(95%CI)为2.8年(2.67-3.00),c9FTD为9.0年(8.09-9.91),c9ALS-FTD为3.0年(2.73-3.27),非典型表型生存期差异较大。
  • 发病年龄较大与c9ALS生存期缩短相关(HR 1.03,95%CI 1.02-1.04,P<.001),与c9FTD相关(HR 1.04,95%CI 1.02-1.06,P<.001),与c9ALS-FTD相关(HR 1.02,95%CI 1.004-1.04,P=.016)。
  • 球部起病与c9ALS生存期缩短相关(HR 1.64,95%CI 1.27-2.08,P<.001)。
  • 家族史、性别、研究所在洲、FTD亚型或额外致病序列变异的存在与生存期无显著关联。
  • 在神经病理确诊的FTLD-TDP-43、MND-TDP-43和FTLD-MND-TDP-43患者中,临床表型异质且影响生存期。

临床怎么用

  • 在遗传咨询中,可依据发病年龄和起病部位(球部起病)对C9orf72重复扩增携带者的生存预后进行分层评估。
  • 对于临床试验设计,发病年龄和球部起病可作为预后分层因素,但需注意研究的方法学局限性。

局限性

  • 作者指出方法学存在固有局限,但未具体说明。
  • 所报告的预后因素与所考察的偏倚指标无显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The c9orf72 repeat expansion (c9 or c9orf72RE) confers a survival disadvantage in amyotrophic lateral sclerosis (ALS); its effect on prognosis in frontotemporal dementia (FTD) remains uncertain. Data on prognostic factors in c9orf72RE disorders could inform patient care, genetic counseling, and trial design. OBJECTIVE: To examine prognostic factors in c9ALS, c9FTD, c9ALS-FTD, and atypical phenotypes. DATA SOURCES: The MEDLINE, Embase, Amed, ProQuest, PsychINFO, CINAHL, and LILACS databases were searched between January 2011 and January 2019. Keywords used were c9orf72 and chromosome 9 open reading frame 72. Reference lists, citations of eligible studies, and review articles were also searched by hand. STUDY SELECTION: Studies reporting disease duration for patients with a confirmed c9orf72RE and a neurological and/or psychiatric disorder were included. A second author independently reviewed studies classified as irrelevant by the first author. Analysis began in January 2019. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 1 author; a further author independently extracted 10% of data. Data were synthesized in univariate and multivariable Cox regression and are displayed as hazard ratios (HR) and 95% confidence intervals. MAIN OUTCOMES AND MEASURES: Survival after symptom onset. RESULTS: Overall, 206 studies reporting on 1060 patients were included from 2878 publications identified (c9ALS: n = 455; c9FTD: n = 296; c9ALS-FTD: n = 198; atypical phenotypes: n = 111); 197 duplicate cases were excluded. The median (95% CI) survival (in years) differed significantly between patients with c9ALS (2.8 [2.67-3.00]), c9FTD (9.0 [8.09-9.91]), and c9ALS-FTD (3.0 [2.73-3.27]); survival in atypical phenotypes varied substantially. Older age at onset was associated with shorter survival in c9ALS (HR, 1.03; 95% CI, 1.02-1.04; P < .001), c9FTD (HR, 1.04; 95% CI, 1.02-1.06; P < .001), and c9ALS-FTD (HR, 1.02; 95% CI, 1.004-1.04; P = .016). Bulbar onset was associated with shorter survival in c9ALS (HR, 1.64; 95% CI, 1.27-2.08; P < .001). Age at onset and bulbar onset ALS remained significant in multivariable regression including variables indicating potential diagnostic ascertainment bias, selection bias, and reporting bias. Family history, sex, study continent, FTD subtype, or the presence of additional pathogenic sequence variants were not significantly associated with survival. Clinical phenotypes in patients with neuropathologically confirmed frontotemporal lobar degeneration-TDP-43, motor neuron disease-TDP-43 and frontotemporal lobar degeneration-motor neuron disease-TDP-43 were heterogenous and impacted on survival. CONCLUSIONS AND RELEVANCE: Several factors associated with survival in c9orf72RE disorders were identified. The inherent limitations of our methodological approach must be considered; nonetheless, the reported prognostic factors were not significantly associated with the bias indicators examined.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Glasmacher SA, Wong C, Pearson IE, et al. Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis. JAMA Neurol. 2020. PMID: 31738367. doi:10.1001/jamaneurol.2019.3924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。